Mavira Capsule 200 mg

Mavira Capsule 200 mg Uses, Dosage, Side Effects, Food Interaction and all others data.

Mavira Capsule 200 mg
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Mavira Capsule 200 mg
Generic	Molnupiravir
Weight	200 mg
Type	Capsule
Therapeutic Class
Manufacturer	Drug International Ltd.
Available Country	Bangladesh
Last Updated:	October 19, 2023 at 6:27 am

Uses

Mavira Capsule 200 mg is an antiviral medicine used to treat mild to moderate C0VID-19 (caused by SARS-CoV-2) in adults who are at risk for developing severe illness. Mavira Capsule 200 mg may help people with C0VID-19 stay out of the hospital and feel better. Emergency use authorized oral therapeutic for the treatment ... Read more

Dosage

Mavira Capsule 200 mg dosage

The recommended dose of Mavira Capsule 200 mg is four 200 mg capsules (4+0+4), every 12 hours for 5 days. Do not give this medicine to children and adolescents aged less than 18 years. The use of Mavira Capsule 200 mg in persons aged less than 18 years has not yet been studied.

Side Effects

Common side effects include diarrhoea, nausea, feeling dizzy, headache.

Precaution

There are limited clinical data available for Mavira Capsule 200 mg. Serious and unexpected adverse events may occur that have not been previously reported with Mavira Capsule 200 mg use.

Interaction

No drug interactions have been identified based on the limited available data. No clinical interaction studies have been performed with Mavira Capsule 200 mg. Mavira Capsule 200 mg is hydrolysed to n-hydroxycytidine (NHC) prior to reaching systemic circulation. Uptake of NHC and metabolism to NHC-TP are mediated by the same pathways involved in endogenous pyrimidine metabolism. NHC is not a substrate of major drug metabolising enzymes or transporters. Based on in vitro studies, neither molnupiravir nor NHC are inhibitors or inducers of major drug metabolising enzymes or inhibitors of major drug transporters. Therefore, the potential for molnupiravir or NHC to interact with concomitant medications is considered unlikely.

Pregnancy & Breastfeeding use

Animal studies with molnupiravir have shown harmful effects to the unborn animal. Mavira Capsule 200 mg is not recommended in pregnancy. Mavira Capsule 200 mg has not been studied in pregnancy and it is not known if Mavira Capsule 200 mg will harm your baby while you are pregnant. If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor for advice. If you can become pregnant, you should use effective birth control while you are taking Mavira Capsule 200 mg and for 4 days after the last dose of Mavira Capsule 200 mg. If you are breast-feeding or are planning to breastfeed, tell your doctor before taking this medicine. Breast-feeding is not recommended during treatment and for 4 days after the last dose of Mavira Capsule 200 mg. This is because it is not known if Mavira Capsule 200 mg gets into breast milk and will be passed to the baby.